N-(2-piperidin-1-yl-ethyl)-benzene-1,2-diamine | 5625-68-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(2-piperidin-1-yl-ethyl)-benzene-1,2-diamine
• 英文别名: 1,2-Benzenediamine, N-[2-(1-piperidinyl)ethyl]-；2-N-(2-piperidin-1-ylethyl)benzene-1,2-diamine
• CAS: 5625-68-3
• 化学式: C₁₃H₂₁N₃
• 分子量: 219.33
• InChiKey: MNIDKMZFDIYUBL-UHFFFAOYSA-N

物化性质

• 沸点：
  393.3±27.0 °C(Predicted)
• 密度：
  1.090±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  41.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  N-(2-piperidin-1-yl-ethyl)-benzene-1,2-diamine 在 溴化氰 作用下， 以 乙醇 为溶剂， 以51%的产率得到2-Amino-1-piperidinoethylbenzimidazole
  参考文献：
  名称：

  [EN] BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME
  [FR] HÉTÉROCYCLES BICYCLIQUES APTES À MODULER DES RÉPONSES DES LYMPHOCYTES T, ET PROCÉDÉS D'UTILISATION ASSOCIÉS

  摘要：

  本公开涉及部分对于双环杂环化合物，例如本文所披露的由式(I)或(II)表示的化合物，以及它们在治疗医学疾病中的应用，如免疫性炎症性疾病，如克罗恩病、溃疡性结肠炎、风湿性疾病、牛皮癣和过敏症。这些化合物被认为可以调节T细胞反应。

  公开号：

  WO2013178815A1
• 作为产物：
  描述：

  1-(2-氨乙基)哌啶 在 palladium on activated charcoal 、 氢气 作用下， 以 乙醇 为溶剂， 生成 N-(2-piperidin-1-yl-ethyl)-benzene-1,2-diamine
  参考文献：
  名称：

  [EN] BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME
  [FR] HÉTÉROCYCLES BICYCLIQUES APTES À MODULER DES RÉPONSES DES LYMPHOCYTES T, ET PROCÉDÉS D'UTILISATION ASSOCIÉS

  摘要：

  本公开涉及部分对于双环杂环化合物，例如本文所披露的由式(I)或(II)表示的化合物，以及它们在治疗医学疾病中的应用，如免疫性炎症性疾病，如克罗恩病、溃疡性结肠炎、风湿性疾病、牛皮癣和过敏症。这些化合物被认为可以调节T细胞反应。

  公开号：

  WO2013178815A1

文献信息

• Aryl substituted benzimidazoles and their use as sodium channel blockers
  申请人：——

  公开号：US20040132777A1

  公开（公告）日：2004-07-08

  This invention relates aryl substituted benzimidazoles of Formula I: 1 or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein R 1 , R 2 , R 10 and n are defined in the specification. The invention is also directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.

  本发明涉及式I的芳基取代苯并咪唑化合物：1或其药学上可接受的盐、前药或溶剂化物，其中R1、R2、R10和n在规范中定义。本发明还涉及使用式I的化合物治疗全脑和局部缺血后的神经损伤，治疗或预防神经退行性疾病，如肌萎缩性侧索硬化症（ALS），以及治疗、预防或缓解急性或慢性疼痛，作为抗耳鸣剂，抗癫痫药物和抗躁狂抑郁药物，局部麻醉剂，抗心律失常药物以及治疗或预防糖尿病神经病变。
• Benzimidazole and imidazole inhibitors of histone deacetylases: Synthesis and biological activity
  作者：Jerome C. Bressi、Ron de Jong、Yiqin Wu、Andy J. Jennings、Jason W. Brown、Shawn O’Connell、Leslie W. Tari、Robert J. Skene、Phong Vu、Marc Navre、Xiaodong Cao、Anthony R. Gangloff

  DOI：10.1016/j.bmcl.2010.03.092

  日期：2010.5

  A series of N-hydroxy-3-[3-(1-substituted-1H-benzoimidazol-2-yl)-phenyl]-acrylamides (5a-5ab) and N-hydroxy-3-[ 3-( 1,4,5-trisubstituted-1H-imidazol-2-yl)-phenyl]-acrylamides (12a-s) were designed, synthesized, and found to be nanomolar inhibitors of human histone deacetylases. Multiple compounds bearing an N1-piperidine demonstrate EC(50)s of 20-100 nM in human A549, HL60, and PC3 cells, in vitro and in vivo hyperacetylation of histones H3 and H4, and induction of p21(waf). Compound 5x displays efficacy in human tumor xenograft models. (C) 2010 Elsevier Ltd. All rights reserved.
• Synthesis and evaluation of 3-anilino-quinoxalinones as glycogen phosphorylase inhibitors
  作者：Joseph Dudash、Yongzheng Zhang、John B. Moore、Richard Look、Yin Liang、Mary Pat Beavers、Bruce R. Conway、Philip J. Rybczynski、Keith T. Demarest

  DOI：10.1016/j.bmcl.2005.07.021

  日期：2005.11

  A series of 3-anilino-quinoxalinones has been identified as a new class of glycogen phosphorylase inhibitors. The lead compound I was identified through high throughput screening as well as through pharmacophore-based electronic screening. Modifications were made to the scaffold of 1 to produce novel analogues, some of which are 25 times more potent than the lead compound. (c) 2005 Elsevier Ltd. All rights reserved.
• [EN] ARYL SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS SODIUM CHANNEL BLOCKERS<br/>[FR] BENZIMIDAZOLES ARYLE SUBSTITUEES ET UTILISATION DE CE COMPOSE COMME BLOQUEURS DE CANAL
  申请人：EURO CELTIQUE SA

  公开号：WO2004011439A3

  公开（公告）日：2004-04-01
• Discovery of 2-iminobenzimidazoles as a new class of trypanothione reductase inhibitor by high-throughput screening
  作者：Georgina A. Holloway、Jonathan B. Baell、Alan H. Fairlamb、Patrizia M. Novello、John P. Parisot、John Richardson、Keith G. Watson、Ian P. Street

  DOI：10.1016/j.bmcl.2006.11.090

  日期：2007.3

  A high-throughput screening campaign of a library of 100,000 lead-like compounds identified 2-iminobenzimidazoles as a novel class of trypanothione reductase inhibitors. These 2-iminobenzimidazoles display potent trypanocidal activity against Trypanosoma brucei rhodesiense, do not inhibit closely related human glutathione reductase and have low cytotoxicity against mammalian cells.